The need for transparency and efficiency in reimbursement decisions relating to drugs for rare diseases

Med Decis Making. 2015 Feb;35(2):145-7. doi: 10.1177/0272989X14563082. Epub 2014 Dec 10.

Authors

Douglas A Coyle¹, Matthew C Cheung², Gerald A Evans³

Affiliations

¹ Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada (DC)
² Division of Hematology/Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Center, University of Toronto, Toronto, ON, Canada (MCC)
³ Division of Infectious Diseases, Department of Medicine, Kingston General Hospital and Queen's University, Kingston, ON, Canada (GAE)

PMID: 25505026
DOI: 10.1177/0272989X14563082

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Cost-Benefit Analysis*
Drug Costs*
Hemoglobinuria, Paroxysmal / drug therapy*
Humans
Rare Diseases / drug therapy*

Substances

Antibodies, Monoclonal, Humanized